Cytotoxic effects in 3T3-L1 mouse and WI-38 human fibroblasts following 72hour and 7day exposures to commercial silica nanoparticles

Stępnik, Maciej; Arkusz, Joanna; Smok-Pieniążek, Anna; Bratek‐Skicki, Anna; Salvati, Anna; Lynch, Iseult; Dawson, Kenneth A.; Gromadzińska, Jolanta; Jong, Wim H. de; Rydzyński, K

doi:10.1016/j.taap.2012.06.002

Cited by 27 publications

(14 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 The emulsion droplets contained positively charged alumina coated silica nanoparticles or lysozyme in water, while the outer phase was a solution of a sulfonated styrene copolymer in toluene. 19,20 The low but finite solubility of s-SEBS in the water phase allows s-SEBS chains to diffuse across the oil-water interface into the aqueous droplet interior where its sulfonate moieties become charged. 18 The silica nanoparticles have a nominal diameter of 21 nm and an isoelectric point of B8.7.…”

Section: Resultsmentioning

confidence: 99%

Soft microcapsules with highly plastic shells formed by interfacial polyelectrolyte–nanoparticle complexation

et al. 2015

View full text Add to dashboard Cite

Composite microcapsules have been aggressively pursued as designed chemical entities for biomedical and other applications. Common preparations rely on multi-step, time consuming processes. Here, we present a single-step approach to fabricate such microcapsules with shells composed of nanoparticle-polyelectrolyte and protein-polyelectrolyte complexes, and demonstrate control of the mechanical and release properties of these constructs. Interfacial polyelectrolyte-nanoparticle and polyelectrolyte-protein complexation across a water-oil droplet interface results in the formation of capsules with shell thicknesses of a few μm. Silica shell microcapsules exhibited a significant plastic response at small deformations, whereas lysozyme incorporated shells displayed a more elastic response. We exploit the plasticity of nanoparticle incorporated shells to produce microcapsules with high aspect ratio protrusions by micropipette aspiration.

show abstract

Section: Resultsmentioning

confidence: 99%

Soft microcapsules with highly plastic shells formed by interfacial polyelectrolyte–nanoparticle complexation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For example, in human endothelial cells small amorphous silica nanospheres of 14–16 nm causes pronounced cytotoxicity in cell survival assays while larger nanoparticles (60 nm, 104 nm and 335 nm) showed significantly less toxicity (Napierska et al, 2009). Results have also suggested some toxicity in cell types such as fibroblasts, pre-adipocytes, endothelial, and melanoma cells dependent on size and surface properties (Huang et al, 2011; Napierska et al, 2009; Stepnik et al, 2012). However, in agreement with our results, 40–80nm silica particles showed no toxicity in HUVEC cells (30,000 NPs/cell) (Bauer et al, 2011) and mesoporous silica nanoparticles were reported to retain over 80% viability in A375 melanoma cells exposed to at a 1000 μg/ml dose (Huang et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Bio-active engineered 50nm silica nanoparticles with bone anabolic activity: Therapeutic index, effective concentration, and cytotoxicity profile in vitro

Sikorski²,

Weitzmann

et al. 2014

Toxicology in Vitro

View full text Add to dashboard Cite

Silica-based nanomaterials are generally considered to be excellent candidates for therapeutic applications particularly related to skeletal metabolism however the current data surrounding the safety of silica based nanomaterials is conflicting. This may be due to differences in size, shape, incorporation of composite materials, surface properties, as well as the presence of contaminants following synthesis. In this study we performed extensive in vitro safety profiling of ~50 nm spherical silica nanoparticles with OH-terminated or Polyethylene Glycol decorated surface, with and without a magnetic core, and synthesized by the Stöber method. Nineteen different cell lines representing all major organ types were used to investigate an in vitro lethal concentration (LC) and results revealed little toxicity in any cell type analyzed. To calculate an in vitro therapeutic index we quantified the effective concentration at 50% response (EC50) for nanoparticle-stimulated mineral deposition activity using primary bone marrow stromal cells (BMSCs). The EC50 for BMSCs was not substantially altered by surface or magnetic core. The calculated Inhibitory concentration 50% (IC50) for pre-osteoclasts was similar to the osteoblastic cells. These results demonstrate the pharmacological potential of certain silica-based nanomaterial formulations for use in treating bone diseases based on a favorable in vitro therapeutic index.

show abstract

“…General observations from the literature indicate that amorphous silica is less toxic than crystalline silica (Jaganathan and Godin 2012), and mesoporous silica NPs are less toxic than colloidal silica NPs (Lee et al 2011). It has also been shown that surface modification of silica NPs can alter the effects of such particles on cell proliferation or oxidative stress (Tsutsumi and Yoshioka 2011; Stępnik et al 2012). It should be noted that Fisichella et al (2009) had observed that mesoporous silica nanoparticles can interfere with MTT assays in other cell types, resulting in overestimations of cytotoxicity.…”

Section: Discussionmentioning

confidence: 99%

Kinetics of silica nanoparticles in the human placenta

et al. 2013

View full text Add to dashboard Cite

The potential medical applications of nanoparticles warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica nanoparticles (NPs) across the placenta was investigated using two models of maternal-fetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay and demonstrated decreased cell viability at concentrations greater than 100 μg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a fetal/maternal ratio of 0.97 ± 0.10 after 2 hours. In contrast, the percentage of silica NPs reaching the fetal perfusate after 6 hours was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25-nm and 50-nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10−6 ± 1.56 × 10−6 cm/sec. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the fetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

show abstract

Cytotoxic effects in 3T3-L1 mouse and WI-38 human fibroblasts following 72hour and 7day exposures to commercial silica nanoparticles

Cited by 27 publications

References 54 publications

Soft microcapsules with highly plastic shells formed by interfacial polyelectrolyte–nanoparticle complexation

Soft microcapsules with highly plastic shells formed by interfacial polyelectrolyte–nanoparticle complexation

Bio-active engineered 50nm silica nanoparticles with bone anabolic activity: Therapeutic index, effective concentration, and cytotoxicity profile in vitro

Kinetics of silica nanoparticles in the human placenta

Contact Info

Product

Resources

About